Surgery Partners Ebit Over Time
| SGRY Stock | USD 23.84 0.43 1.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Surgery Partners Performance and Surgery Partners Correlation. Surgery |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Surgery Partners. If investors know Surgery will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Surgery Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 23.69 | Quarterly Revenue Growth 0.143 | Return On Assets 0.039 | Return On Equity 0.0308 |
The market value of Surgery Partners is measured differently than its book value, which is the value of Surgery that is recorded on the company's balance sheet. Investors also form their own opinion of Surgery Partners' value that differs from its market value or its book value, called intrinsic value, which is Surgery Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Surgery Partners' market value can be influenced by many factors that don't directly affect Surgery Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Surgery Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Surgery Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Surgery Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Surgery Partners and related stocks such as Pennant Group, Ensign Group, and Encompass Health Corp Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PNTG | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 15.4 M | 20.6 M | 5.7 M | 19.1 M | 4.7 M | 19.7 M | 25.5 M | 17 M |
| ENSG | 5.9 M | 90.9 M | 91.3 M | 91.4 M | 73.5 M | 93.9 M | 81.7 M | 96.2 M | 128.9 M | 129.2 M | 227 M | 264.9 M | 298 M | 280.8 M | 294.9 M |
| EHC | (1.7 M) | 362.3 M | 434.1 M | 458.8 M | 484.3 M | 569.5 M | 651.2 M | 649.4 M | 681.6 M | 692.5 M | 572.2 M | 659.4 M | 630.2 M | 750.7 M | 605.7 M |
| HCSG | 1.7 M | 51.4 M | 59.3 M | 52.9 M | 21.2 M | 80.7 M | 115.1 M | 120.8 M | 100.4 M | 70.5 M | 130.6 M | 63.2 M | 47.5 M | 60.9 M | 38.2 M |
| EHAB | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 105.4 M | 148.3 M | (10.5 M) | (47.4 M) | (45 M) |
| INNV | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.5 M) | (6.4 M) | (5 M) | 39.7 M | 50.3 M | (18.2 M) | (4.7 M) | (49.3 M) | (17.8 M) | (16.9 M) |
| NHC | 30.9 M | 77.8 M | 91.7 M | 97.3 M | 87.4 M | 87.9 M | 84.1 M | 79.4 M | 78.4 M | 78.9 M | (826.4 M) | (885.3 M) | (1 B) | 89.1 M | 93.5 M |
| SEM | 118.3 M | 314 M | 383.6 M | 341.3 M | 336.1 M | 380.6 M | 431.5 M | 456.4 M | 417.3 M | 471.9 M | 477.6 M | 570.1 M | 379.5 M | 554.9 M | 391 M |
| CCM | 102.3 M | 31.6 M | 68.3 M | 24.8 M | 19.2 M | (90.5 M) | (60.7 M) | (166.8 M) | (266.2 M) | (437.3 M) | (307.5 M) | (455.4 M) | (719.5 M) | (389.9 M) | (370.4 M) |
| UHS | 68.5 M | 897.1 M | 944.7 M | 999.4 M | 1.1 B | 1.3 B | 1.3 B | 1.3 B | 1.2 B | 1.2 B | 1.4 B | 1.4 B | 1.1 B | 1.1 B | 1.2 B |
| ADUS | 5.2 M | 14 M | 15.3 M | 15.5 M | 18.1 M | 16 M | 18.3 M | 24.1 M | 26.9 M | 34.8 M | 45.1 M | 66.2 M | 69.1 M | 92.4 M | 97.1 M |
Surgery Partners and related stocks such as Pennant Group, Ensign Group, and Encompass Health Corp Ebit description
My Equities
My Current Equities and Potential Positions
| Surgery Partners | SGRY |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Tennessee; U.S.A |
| Exchange | NASDAQ Exchange |
USD 23.84
Additional Tools for Surgery Stock Analysis
When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.